Advertisement

Esophageal and Gastroesophageal Junction Tumors

  • Ebru Cilbir
  • Suayib YalcinEmail author
Chapter

Abstract

Esophageal cancer is a devastating disease with low survival rates. The management of locoregional disease has evolved over the past decade. Optimal staging and optimal treatment decisions according to stage, histologic type, and the location of disease are very important. A multidisciplinary approach to the patient is the major contributor to success.

Keywords

Esophageal cancer Gastroesophageal junction Tobacco Alcohol Squamous cell carcinoma Adenocarcinoma Radiotherapy Chemoradiotherapy Gastroesophageal reflux disease Esophagectomy Endoscopic therapy Adjuvant Neoadjuvant Resectable Unresectable Inoperable Dysphagia 

References

  1. 1.
    Anonymous. Estimated cancer incidence, mortality and prevalence worldwide in 2012. www.globocan.iarc.fr; Globocan 2012.
  2. 2.
    Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–7.CrossRefGoogle Scholar
  3. 3.
    Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6):1149–58.CrossRefPubMedGoogle Scholar
  4. 4.
    Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomark Prev. 2010;19(6):1468–70.CrossRefGoogle Scholar
  5. 5.
    Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149(2):302–17 e301.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Dolan K, Sutton R, Walker SJ, Morris AI, Campbell F, Williams EM. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer. 1999;80(5-6):834–42.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    SEER 18 2006–2012.Google Scholar
  8. 8.
    Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165(12):1424–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut, betel quid, oral snuff, cigarette smoking and the risk of oesophageal squamous-cell carcinoma in South Asians: a multicentre case-control study. Eur J Cancer. 2012;48(5):655–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Islami F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F. High-temperature beverages and foods and esophageal cancer risk – a systematic review. Int J Cancer. 2009;125(3):491–524.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Li X, Gao C, Yang Y, Zhou F, Li M, Jin Q, et al. Systematic review with meta-analysis: the association between human papillomavirus infection and oesophageal cancer. Aliment Pharmacol Ther. 2014;39(3):270–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Chaber-Ciopinska A, Kiprian D, Kawecki A, Kaminski MF. Surveillance of patients at high-risk of squamous cell esophageal cancer. Best Pract Res Clin Gastroenterol. 2016;30(6):893–900.CrossRefPubMedGoogle Scholar
  13. 13.
    Wright E, Schofield PT, Molokhia M. Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis. BMJ Open. 2015;5(12):e007133.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310(6):627–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international beacon consortium. J Natl Cancer Inst. 2010;102(17):1344–53.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett’s esophagus. Am J Gastroenterol. 2008;103(2):292–300.CrossRefPubMedGoogle Scholar
  17. 17.
    Thrift AP, Shaheen NJ, Gammon MD, Bernstein L, Reid BJ, Onstad L, et al. Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014;106(11):dju252.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett’s oesophagus. Gut. 1997;40(1):9–13.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Loffeld RJ, Ten Tije BJ, Arends JW. Prevalence and significance of Helicobacter pylori in patients with Barrett’s esophagus. Am J Gastroenterol. 1992;87(11):1598–600.PubMedGoogle Scholar
  20. 20.
    Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007;5(12):1413–7, 1417 e1411-1412.CrossRefPubMedGoogle Scholar
  21. 21.
    Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rice TW, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, Wijnhoven BP, et al. Worldwide esophageal cancer collaboration: pathologic staging data. Dis Esophagus. 2016;29(7):724–33.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rice TW, Apperson-Hansen C, DiPaola LM, Semple ME, Lerut TE, Orringer MB, et al. Worldwide esophageal cancer collaboration: clinical staging data. Dis Esophagus. 2016;29(7):707–14.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rice TW, Lerut TE, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM, et al. Worldwide esophageal cancer collaboration: Neoadjuvant pathologic staging data. Dis Esophagus. 2016;29(7):715–23.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Rice TW, Kelsen DP, Blackstone EH, et al. Esophagus and esophagogastric junction. In: Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. p. 185–202.CrossRefGoogle Scholar
  27. 27.
    Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15(1):277–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. JAMA. 1999;281(17):1623–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Pennathur A, Farkas A, Krasinskas AM, Ferson PF, Gooding WE, Gibson MK, et al. Esophagectomy for t1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009;87(4):1048–54.. discussion 1054-1045.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57(9):1200–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Markar SR, Mackenzie H, Ni M, Huddy JR, Askari A, Faiz O, et al. The influence of procedural volume and proficiency gain on mortality from upper GI endoscopic mucosal resection. Gut. 2018;67(1):79–85.CrossRefPubMedGoogle Scholar
  32. 32.
    Mannath J, Ragunath K. Role of endoscopy in early oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2016;13(12):720–30.CrossRefPubMedGoogle Scholar
  33. 33.
    Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc. 2007;65(1):3–10.CrossRefPubMedGoogle Scholar
  34. 34.
    Pech O, Gossner L, May A, Vieth M, Stolte M, Ell C. Endoscopic resection of superficial esophageal squamous-cell carcinomas: Western experience. Am J Gastroenterol. 2004;99(7):1226–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Sgourakis G, Gockel I, Lang H. Endoscopic and surgical resection of t1a/t1b esophageal neoplasms: a systematic review. World J Gastroenterol. 2013;19(9):1424–37.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Manner H, May A, Pech O, Gossner L, Rabenstein T, Gunter E, et al. Early Barrett’s carcinoma with “low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103(10):2589–97.CrossRefPubMedGoogle Scholar
  37. 37.
    Sun F, Yuan P, Chen T, Hu J. Efficacy and complication of endoscopic submucosal dissection for superficial esophageal carcinoma: a systematic review and meta-analysis. J Cardiothorac Surg. 2014;9:78.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Nakagawa K, Koike T, Iijima K, Shinkai H, Hatta W, Endo H, et al. Comparison of the long-term outcomes of endoscopic resection for superficial squamous cell carcinoma and adenocarcinoma of the esophagus in Japan. Am J Gastroenterol. 2014;109(3):348–56.CrossRefPubMedGoogle Scholar
  39. 39.
    www.nccn.org. NCCN guidelines, version 2.2016, esophageal and esophagogastric junction tumors.
  40. 40.
    Pech O, Bollschweiler E, Manner H, Leers J, Ell C, Holscher AH. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers. Ann Surg. 2011;254(1):67–72.CrossRefPubMedGoogle Scholar
  41. 41.
    Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong LM, Dunagan KT, et al. Endoscopic and surgical treatment of mucosal (t1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137(3):815–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Das A, Singh V, Fleischer DE, Sharma VK. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103(6):1340–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Chadwick G, Groene O, Markar SR, Hoare J, Cromwell D, Hanna GB. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett’s esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc. 2014;79(5):718–31 e713.CrossRefPubMedGoogle Scholar
  44. 44.
    Pech O, May A, Manner H, Behrens A, Pohl J, Weferling M, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014;146(3):652–60 e651.CrossRefGoogle Scholar
  45. 45.
    Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–88.CrossRefGoogle Scholar
  46. 46.
    Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–8.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Bergman JJ, Zhang YM, He S, Weusten B, Xue L, Fleischer DE, et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc. 2011;74(6):1181–90.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–7.CrossRefGoogle Scholar
  49. 49.
    Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefGoogle Scholar
  51. 51.
    Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32(23):2416–22.CrossRefGoogle Scholar
  52. 52.
    Czito BG, Palta M, Willett CG. Results of the FFCD 9901 trial in early-stage esophageal carcinoma: is it really about neoadjuvant therapy? J Clin Oncol. 2014;32(23):2398–400.CrossRefPubMedGoogle Scholar
  53. 53.
    Kato H, Tachimori Y, Watanabe H, Itabashi M, Hirota T, Yamaguchi H, et al. Intramural metastasis of thoracic esophageal carcinoma. Int J Cancer. 1992;50(1):49–52.CrossRefPubMedGoogle Scholar
  54. 54.
    Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 2001;19(7):1970–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Peters JH, Oberg S, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg. 1999;117(1):16–23.. discussion 23-15.CrossRefPubMedGoogle Scholar
  56. 56.
    Stein HJ, Hutter J, Feith M, von Rahden BH. Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Semin Thorac Cardiovasc Surg. 2007;19(1):72–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246(1):1–8.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Ito H, Clancy TE, Osteen RT, Swanson RS, Bueno R, Sugarbaker DJ, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg. 2004;199(6):880–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Daiko H, Hayashi R, Saikawa M, Sakuraba M, Yamazaki M, Miyazaki M, et al. Surgical management of carcinoma of the cervical esophagus. J Surg Oncol. 2007;96(2):166–72.CrossRefPubMedGoogle Scholar
  60. 60.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefGoogle Scholar
  61. 61.
    Bedard EL, Inculet RI, Malthaner RA, Brecevic E, Vincent M, Dar R. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 2001;91(12):2423–30.CrossRefPubMedGoogle Scholar
  62. 62.
    Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol. 2009;4(10):1264–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Chen J, Pan J, Liu J, Li J, Zhu K, Zheng X, et al. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013;86(4):671–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Tachibana M, Yoshimura H, Kinugasa S, Shibakita M, Dhar DK, Ueda S, et al. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol. 2003;29(7):580–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan clinical oncology group study--JCOG9204. J Clin Oncol. 2003;21(24):4592–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Speicher PJ, Englum BR, Ganapathi AM, Mulvihill MS, Hartwig MG, Onaitis MW, et al. Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma. J Thorac Oncol. 2015;10(1):181–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.CrossRefPubMedGoogle Scholar
  68. 68.
    Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol. 2010;16(30):3793–803.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.CrossRefPubMedGoogle Scholar
  70. 70.
    Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22(1):1–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Sykes AJ, Burt PA, Slevin NJ, Stout R, Marrs JE. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol. 1998;48(1):15–21.CrossRefPubMedGoogle Scholar
  72. 72.
    Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. Int 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.CrossRefPubMedGoogle Scholar
  74. 74.
    Wong RK, Malthaner R. Withdrawn. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2010;(1):CD002092.Google Scholar
  75. 75.
    Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305–14.CrossRefPubMedGoogle Scholar
  76. 76.
    Honing J, Smit JK, Muijs CT, Burgerhof JG, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25(3):638–43.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (cross): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefGoogle Scholar
  78. 78.
    Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.CrossRefGoogle Scholar
  79. 79.
    Kranzfelder M, Schuster T, Geinitz H, Friess H, Buchler P. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 2011;98(6):768–83.CrossRefPubMedGoogle Scholar
  80. 80.
    Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005;104(7):1349–55.CrossRefPubMedGoogle Scholar
  81. 81.
    Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91(11):2165–74.CrossRefPubMedGoogle Scholar
  82. 82.
    Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;56(2):328–34.CrossRefPubMedGoogle Scholar
  83. 83.
    Wang CC, Cheng JC, Tsai CL, Lee JM, Huang PM, Lin CC, et al. Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. Radiother Oncol. 2015;115(1):9–15.CrossRefPubMedGoogle Scholar
  84. 84.
    Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23(19):4330–7.CrossRefGoogle Scholar
  85. 85.
    Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys. 2011;80(4):996–1001.CrossRefPubMedGoogle Scholar
  86. 86.
    Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001;92(2):279–86.CrossRefPubMedGoogle Scholar
  87. 87.
    Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;57(1):120–7.CrossRefPubMedGoogle Scholar
  88. 88.
    Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004;100(11):2347–54.CrossRefPubMedGoogle Scholar
  89. 89.
    Pasini F, de Manzoni G, Zanoni A, Grandinetti A, Capirci C, Pavarana M, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer. 2013;119(5):939–45.CrossRefPubMedGoogle Scholar
  90. 90.
    Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.CrossRefGoogle Scholar
  91. 91.
    Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. Pet to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797–805.CrossRefPubMedGoogle Scholar
  92. 92.
    zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52(8):1189–96.CrossRefGoogle Scholar
  93. 93.
    Goodman KA, Hall N, Bekaii-Saab TS, Ou F-S, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Perry K, Frankel WL, Venook AP, O’Reilly EM, Ilson DH. Survival outcomes from CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. J Clin Oncol. 2018;36(15_suppl):4012.CrossRefGoogle Scholar
  94. 94.
    Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.CrossRefPubMedGoogle Scholar
  95. 95.
    Stahl M, Wilke H, Lehmann N, et al. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus (abstract). J Clin Oncol, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008;26(15S (May 20 Supplement)):4530.CrossRefGoogle Scholar
  96. 96.
    Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.CrossRefPubMedGoogle Scholar
  97. 97.
    Bonnetain F, Bouche O, Michel P, Mariette C, Conroy T, Pezet D, et al. A comparative longitudinal quality of life study using the spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): Chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol. 2006;17(5):827–34.CrossRefPubMedGoogle Scholar
  98. 98.
    Vincent J, Mariette C, Pezet D, Huet E, Bonnetain F, Bouche O, et al. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone. Eur J Cancer. 2015;51(13):1683–93.CrossRefPubMedGoogle Scholar
  99. 99.
    Best LM, Mughal M, Gurusamy KS. Non-surgical versus surgical treatment for oesophageal cancer. Cochrane Database Syst Rev. 2016;(3):CD011498.Google Scholar
  100. 100.
    Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, et al. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. Ann Surg Oncol. 2014;21(12):3744–50.CrossRefPubMedGoogle Scholar
  101. 101.
    Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014;32(30):3400–5.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013;24(5):1262–6.CrossRefPubMedGoogle Scholar
  103. 103.
    Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, et al. Outcomes of patients with esophageal cancer staged with [(1)(8)F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 2010;28(31):4714–21.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C. Ineffectiveness of (1)(8)F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2013;258(1):66–76.CrossRefPubMedGoogle Scholar
  105. 105.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefGoogle Scholar
  106. 106.
    Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.CrossRefGoogle Scholar
  107. 107.
    Al-Batran SE, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. In: ASCO 2017 Annual Meeting. 2017: Abstract 4004.CrossRefGoogle Scholar
  108. 108.
    Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007;109(1):125–34.CrossRefPubMedGoogle Scholar
  109. 109.
    Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol. 2011;23(3):182–8.CrossRefGoogle Scholar
  110. 110.
    Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong SK, Ng EK. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013;24(1):165–71.CrossRefPubMedGoogle Scholar
  111. 111.
    Medical Research Council Oesophageal Cancer Working G. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–33.CrossRefGoogle Scholar
  112. 112.
    Tougeron D, Di Fiore F, Hamidou H, Rigal O, Paillot B, Michel P. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. Oncology. 2007;73(5–6):328–34.CrossRefPubMedGoogle Scholar
  113. 113.
    Versteijne E, van Laarhoven HW, van Hooft JE, van Os RM, Geijsen ED, van Berge Henegouwen MI, et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: Locoregional recurrence pattern. Dis Esophagus. 2015;28(5):453–9.CrossRefPubMedGoogle Scholar
  114. 114.
    Lin SH, Zhang N, Godby J, Wang J, Marsh GD, Liao Z, et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer. 2016;122(6):917–28.CrossRefPubMedGoogle Scholar
  115. 115.
    Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008;26(28):4551–6.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Homs MY, vd Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev. 2006;(4):CD004063.Google Scholar
  117. 117.
    Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3):CD004064.Google Scholar
  118. 118.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefGoogle Scholar
  119. 119.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.CrossRefPubMedGoogle Scholar
  120. 120.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the v325 study group. J Clin Oncol. 2006;24(31):4991–7.CrossRefPubMedGoogle Scholar
  121. 121.
    Okines AF, Asghar U, Cunningham D, Ashley S, Ashton J, Jackson K, et al. Rechallenge with platinum plus fluoropyrimidine +/− epirubicin in patients with oesophagogastric cancer. Oncology. 2010;79(1–2):150–8.CrossRefPubMedGoogle Scholar
  122. 122.
    Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.CrossRefPubMedGoogle Scholar
  123. 123.
    Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (cougar-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78–86.CrossRefPubMedGoogle Scholar
  124. 124.
    Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer. 2016;114(4):381–7.CrossRefPubMedPubMedCentralGoogle Scholar
  125. 125.
    Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438–44.CrossRefPubMedGoogle Scholar
  126. 126.
    Tarazona N, Smyth EC, Peckit C, Chau I, Watkins D, Rao S, et al. Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. Ther Adv Med Oncol. 2016;8(2):104–12.CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (regard): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.CrossRefGoogle Scholar
  128. 128.
    Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (rainbow): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.CrossRefPubMedGoogle Scholar
  129. 129.
    Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–54.CrossRefPubMedGoogle Scholar
  130. 130.
    Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.CrossRefGoogle Scholar
  131. 131.
    Janjigian YY, Ott PA, Calvo E, et al. Nivolumab ± ipilimumab in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer: Checkmate 032 study. In: ASCO 2017 Annual Meeting. 2017; Abstract 4014.Google Scholar
  132. 132.
    Fuchs CS, Doi T, Jang RW, et al. Efficacy and safety of pembrolizumab monotherapy in patients with previously treated advanced gastric cancer: KEYNOTE 059 study-cohort 1. In: ASCO 2017 Annual Meeting. 2017; Abstract 4003.Google Scholar
  133. 133.
    Bang YJ, Muro K, Fuchs CS, et al. KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. In: ASCO 2017 Annual Meeting. 2017; Abstract 4012.CrossRefGoogle Scholar
  134. 134.
    Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Yuan S, Koshiji M, Csiki I, Bennouna J. Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028. J Clin Oncol. 2015;33(15_suppl):4010.CrossRefGoogle Scholar
  135. 135.
    Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. [Clinical Trial, Phase II Multicenter Study]. 2017;18(5):631–9.Google Scholar
  136. 136.
    Battersby NJ, Bonney GK, Subar D, Talbot L, Decadt B, Lynch N. Outcomes following oesophageal stent insertion for palliation of malignant strictures: a large single centre series. J Surg Oncol. 2012;105(1):60–5.CrossRefPubMedGoogle Scholar
  137. 137.
    Stewart DJ, Balamurugan R, Everitt NJ, Ravi K. Ten-year experience of esophageal self-expanding metal stent insertion at a single institution. Dis Esophagus. 2013;26(3):276–81.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyDışkapı Yıldırım Beyazıt Education and Research HospitalAnkaraTurkey
  2. 2.Department of Internal Medicine, Division of Medical OncologyHacettepe University School of Medicine, Institute of CancerAltındağ, AnkaraTurkey

Personalised recommendations